MedPath

湖北午时医药研究院有限公司

Ownership
-
Established
2014-12-04
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

9

NMPA:9

Drug Approvals

Roxatidine Acetate Hydrochloride for Injection

Product Name
注射用盐酸罗沙替丁醋酸酯
Approval Number
国药准字H20254006
Approval Date
Apr 22, 2025
NMPA

Doxofylline Injection

Product Name
多索茶碱注射液
Approval Number
国药准字H20253668
Approval Date
Mar 18, 2025
NMPA

Pranoprofen Eye Drops

Product Name
普拉洛芬滴眼液
Approval Number
国药准字H20253502
Approval Date
Mar 4, 2025
NMPA

Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution

Product Name
氨溴特罗口服溶液
Approval Number
国药准字H20249821
Approval Date
Dec 25, 2024
NMPA

Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution

Product Name
氨溴特罗口服溶液
Approval Number
国药准字H20249809
Approval Date
Dec 25, 2024
NMPA

Phloroglucinol Injection

Product Name
间苯三酚注射液
Approval Number
国药准字H20249634
Approval Date
Dec 1, 2024
NMPA

Potassium Sodium Hydrogen Citrate Granules

Product Name
枸橼酸氢钾钠颗粒
Approval Number
国药准字H20249054
Approval Date
Oct 16, 2024
NMPA

金银花合剂

Approval Number
国药准字Z20063228
Approval Date
Nov 24, 2020
NMPA

金银花露

Approval Number
国药准字Z36020458
Approval Date
May 29, 2020
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.